Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study | Zendy

Valeria Cento | Zendy; M. Aragri | Zendy; Elisabetta Teti | Zendy; Ennio Polilli | Zendy; Ada Bertoli | Zendy; L Biland | Zendy; Silvia Barbaliscia | Zendy; V.C. Di Maio | Zendy; A Pieri | Zendy; Valeria Pace Palitti | Zendy; Loredana Sarmati | Zendy; Giustino Parruti | Zendy; Massimo Andreoni | Zendy; Carlo Federico Perno | Zendy; Francesca CeccheriniSilberstein | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study

Author(s) -

Valeria Cento,

M. Aragri,

Elisabetta Teti,

Ennio Polilli,

Ada Bertoli,

L Biland,

Silvia Barbaliscia,

V.C. Di Maio,

A Pieri,

Valeria Pace Palitti,

Loredana Sarmati,

Giustino Parruti,

Massimo Andreoni,

Carlo Federico Perno,

Francesca CeccheriniSilberstein

Publication year - 2017

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkx302

Subject(s) - ribavirin , discontinuation , medicine , regimen , context (archaeology) , ns5a , clearance , viral load , hepatitis c virus , virology , human immunodeficiency virus (hiv) , hepacivirus , virus , biology , paleontology , urology

Pretreatment evaluation of HCV-infected patients is a complex interplay between multiple clinical and viral parameters, leading to a tailored approach that may bring real-life sustained virological response (SVR) rates close to 98%-99%.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research